Thermo Fisher Scientific Long Term Debt

As of the most recent data (June 2026), TMO shows a long-term debt of $39B. That compares with $33B in the prior-year period — up 18.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, TMO's long-term debt is now $39B (was $33B) — a 18.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Thermo Fisher Scientific is outperforming or lagging.

Tracking TMO's long-term debt over time shows whether Thermo Fisher Scientific is scaling, shrinking, or reshaping that part of the business. The current reading is $39B That compares with $33B in the prior-year period — up 18.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Thermo Fisher Scientific's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $39B) with ownership activity and broader fundamentals.

Thermo Fisher Scientific's long-term debt is $39B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.